Prices are updated after-hours

Professional, Scientific, and Technical Services 2021 - 06 - 21

UpHealth Inc

UPH | $0.3 9.13% 0.0% 350K

(0.0% 1d) (0.0% 1m) (-82.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (3.3% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 5,332,649
https://www.gigcapital2.com
Sec Filling | Patents | 2 employees

(United States) GigCapital Global is a Private-to-Public Equity investment group, sponsoring and operating Special Purpose Acquisition Companies ('SPAC', also known as Blank-Check companies). Founded in 2017 by Dr. Avi Katz, the GigCapital Group and its sponsored SPACs are led by an affiliated team of technology industry experts, deploying a unique Mentor-Investors™ methodology to partner with exceptional privately-held and U.S. and non-U.S. public technology companies led by dedicated, innovative entrepreneurs. The GigCapital Group companies offer financial, operational and executive mentoring to U.S. and global private, and non-U.S. public companies, in order to accelerate their path from inception and as a privately-held entity into the growth-stage as a publicly traded company in the U.S. The partnership of the GigCapital Group with these companies continues through an organic and roll-up strategy growth post the transition to a public company.

msa acquisitions spac blank check

add to watch list Paper trade email alert is off

Convey Holding Parent Inc

CNVY 4 | $10.51 0.0%

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-0.5% 3d) (0.0% 7d) (239.48% volume)
Earnings Calendar:
Market Cap: $ 769,270,737
https://www.conveyhealthsolutions.com
Sec Filling | Patents | 3000 employees

Convey is a specialized healthcare technology and services company that is committed to providing clients with healthcare-specific, compliant member support solutions utilizing technology, engagement, and analytics. Convey's administrative solutions for government-sponsored health plans help to optimize member interactions, ensure compliance, and support end-to-end Medicare processes. By combining its purpose-built technology platforms with dedicated and flexible business process solutions, Convey creates better business results and better healthcare consumer experiences on behalf of business customers and partners. Convey's clients include some of the nation's leading health insurance plans and pharmacy benefit management firms. Convey's healthcare-focused teams help millions of Americans navigate the complex Medicare Advantage and Part D landscape.

optical ycombinator

add to watch list Paper trade email alert is off

Beauty Health Company (The) - Class A

SKIN | $3.25 -5.25% -5.54% 1.2M

Professional, Scientific, and T...

(0.0% 1d) (-24.1% 1m) (-75.1% 1y) (0.0% 2d) (0.0% 3d) (-7.0% 7d) (8.5% volume)
Earnings Calendar: 2024-03-12
Market Cap: $ 401,242,800
https://www.beautyhealth.com/
Sec Filling | Patents | n/a employees

BeautyHealth is a category-creating beauty health company focused on bringing innovative products to market. Its flagship brand, HydraFacial, is a non-invasive and approachable beauty health platform and ecosystem with a powerful community of estheticians, consumers and partners, bridging medical and consumer retail to democratize and personalize skin care solutions for the masses. Leading the charge in beauty health as a category-creator, HydraFacial uses a unique delivery system to cleanse, extract, and hydrate with their patented hydradermabrasion technology and super serums that are made with nourishing ingredients, providing an immediate outcome and creating an instantly gratifying glow in just three steps and 30 minutes. HydraFacial® and Perk™ products are available in over 87 countries with over 16,000 delivery systems globally and millions of treatments performed each year.

brands msa skin treatment 3d

add to watch list Paper trade email alert is off

Synaptogenix Inc

SNPX | $4.33 -7.08% -7.62% 30K

Professional, Scientific, and T...

(0.0% 1d) (2341.5% 1m) (380.0% 1y) (0.0% 2d) (0.0% 3d) (8.6% 7d) (30.76% volume)
Earnings Calendar:
Market Cap: $ 117,487,401

Sec Filling | Patents | 5 employees

synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.

add to watch list Paper trade email alert is off

Unicycive Therapeutics Inc

UNCY | $1.08 -0.92% -0.93% 230K

Professional, Scientific, and T...

(0.0% 1d) (-23.2% 1m) (-32.3% 1y) (0.0% 2d) (-6.0% 3d) (-4.4% 7d) (550.49% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 37,536,951
https://unicycive.com
Sec Filling | Patents | 2021 employees

Unicycive is a biotechnology company developing novel treatment for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

treatment kidney

add to watch list Paper trade email alert is off

Panbela Therapeutics Inc

PBLA | $0.4895 -6.31% 66K

Professional, Scientific, and T...

(0.0% 1d) (-18.8% 1m) (-96.3% 1y) (0.0% 2d) (0.0% 3d) (-3.7% 7d) (49.66% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 2,376,454
http://www.sunbiopharma.com/
Sec Filling | Patents | 6 employees

(US) Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. isdedicated to treating patients with pancreatic cancer and exploring SBP-101's potential for efficacy in combination with other agents and in treating other types of cancer.

cancer treatment pancreatic

add to watch list Paper trade email alert is off

Quantum-Si Incorporated - Class A

QSI | $1.57 3.97% 3.82% 730K

Professional, Scientific, and T...

(0.0% 1d) (-20.0% 1m) (-3.8% 1y) (0.0% 2d) (-0.7% 3d) (-8.4% 7d) (NaN% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 191,276,895
https://quantum-si.com
Sec Filling | Patents | 115 employees

Quantum-Si Incorporated develops protein sequencing platform. The Company offers semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.

drug discovery diagnostics semiconductor chip

add to watch list Paper trade email alert is off

Verve Therapeutics Inc

VERV | News | $6.64 -0.3% -0.3% 1.1M

Professional, Scientific, and T...

(0.0% 1d) (-49.6% 1m) (-57.4% 1y) (0.0% 2d) (0.0% 3d) (-7.8% 7d) (-100.0% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 555,232,013
https://www.vervetx.com
Sec Filling | Patents | 63 employees

Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.

genetic cardiovascular

add to watch list Paper trade email alert is off

Biomea Fusion Inc

BMEA | $10.87 -2.6% -2.67% 1.3M

Professional, Scientific, and T...

(0.0% 1d) (-24.3% 1m) (-59.2% 1y) (0.0% 2d) (0.0% 3d) (-4.5% 7d) (114.15% volume)
Earnings Calendar: 2023-11-06
Market Cap: $ 390,117,343
https://www.biomeafusion.com
Sec Filling | Patents | 12 employees

Biomea Fusion, Inc. operates as a biopharmaceutical company. The Company focuseS on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea Fusion serves customers in the United States.

genetic cancer msa

add to watch list Paper trade email alert is off

Cyclo Therapeutics Inc - Class A

CYTH | $1.19 -0.83% -0.84% 57K

Professional, Scientific, and T...

(0.0% 1d) (-16.1% 1m) (69.2% 1y) (0.0% 2d) (0.0% 3d) (-3.2% 7d) (93.73% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 34,171,731
https://www.cyclotherapeutics.com
Sec Filling | Patents | 8 employees

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development.

cholesterol genetic alzheimer alzheimer’s

add to watch list Paper trade email alert is off

Century Therapeutics Inc

IPSC | $3.06 2.86% 2.78% 110K

Professional, Scientific, and T...

(0.0% 1d) (-43.3% 1m) (-8.4% 1y) (0.0% 2d) (0.0% 3d) (-22.6% 7d) (-37.1% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 198,342,661
https://www.centurytx.com/
Sec Filling | Patents | 102 employees

(US) Century Therapeutics, Inc. specializes in adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first generation cell therapies as well as provides testing and research services.

t-cell cancer

add to watch list Paper trade email alert is off

Lyell Immunopharma Inc

LYEL | $2.24 -3.86% -4.02% 1.1M

Professional, Scientific, and T...

(0.0% 1d) (17.0% 1m) (6.2% 1y) (0.0% 2d) (0.0% 3d) (-0.8% 7d) (4.71% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 569,175,737
https://lyell.com
Sec Filling | Patents | 189 employees

Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. The Company focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes. Lyell is based in South San Francisco, Seattle and Bothell, Washington.

genetic t-cell renewable

add to watch list Paper trade email alert is off

Nautilus Biotechnology Inc

NAUT | $2.46 5.13% 4.88% 53K

Professional, Scientific, and T...

(0.0% 1d) (-11.0% 1m) (-9.3% 1y) (0.0% 2d) (0.0% 3d) (-1.2% 7d) (-31.3% volume)
Earnings Calendar: 2024-02-28
Market Cap: $ 307,741,277

Sec Filling | Patents | 134 employees

born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. the extraordinary team at nautilus represents a wide spectrum of disciplines and expertise, including: protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.

diagnostics chip

add to watch list Paper trade email alert is off